In breast cancer, ANRIL was found to be predominantly located in the nucleus, and nuclear ANRIL positively correlated with periostin expression, suggesting that the subcellular localization of ANRIL impacts cancer progression (89). This evidence concerns the gene CDKN2B-AS1 and breast carcinoma.